Connecticut hearing draws wide support for pilot overdose‑prevention centers
Loading...
Summary
Hundreds of residents, clinicians and people with lived experience urged the Public Health Committee to pass SB 195, saying supervised overdose‑prevention centers would save lives, reduce public drug use and connect people to treatment; state health officials said legal and regulatory questions remain.
Senate Bill 195, which would authorize a limited pilot of state‑regulated overdose‑prevention centers, drew sustained public testimony from clinicians, harm‑reduction providers, family members and people in recovery at a long Public Health Committee hearing. Supporters told stories of loved ones who died after using alone and cited evidence from Rhode Island and New York showing that supervised consumption programs reduce fatal overdoses and increase links to care.
‘‘People cannot begin recovery if they are dead,’’ said a parent and longtime advocate who lost a child to an overdose. Service providers described how centers combine supervised consumption with wrap‑around services — drug‑checking, wound care, case management, housing referrals and quick access to medications for opioid use disorder — and said those integrated services reduce emergency‑medical responses and public syringe litter.
Public‑health researchers and operators of state‑sanctioned programs in neighboring jurisdictions testified about preliminary data: Rhode Island’s state‑authorized site reported thousands of visits and dozens of life‑saving interventions in its first year; New York City sites report reduced public consumption and hundreds of reversals. Visitors from Providence’s Project Weber Renew described how a regulated, clinical structure let them operate without federal interference so far.
Opponents and cautious lawmakers pressed witnesses on the legality of supervised consumption under federal drug statutes and asked whether centers would encourage use. Supporters and legal experts said states have constitutional police powers to adopt public‑health measures and pointed to recent state authorizations elsewhere. Many witnesses emphasized that the goal is harm reduction and pathways to treatment, not promotion of drug use.
The Department of Public Health acknowledged the need to protect patients and staff and offered written comments on several bills; agency officials also noted outstanding legal and regulatory questions and said they would continue to consult with the committee. Lawmakers asked for additional data and operational details before deciding on a pilot.
Next steps: Committee leaders said they would schedule stakeholder briefings and follow‑up meetings to address the legal questions, operational design and funding. If the legislature authorizes a pilot, supporters expect the sites to be limited, regulated and tied to evaluation requirements.
